Earle A. Chiles Research Institute

Two early phase trials testing the safety and tolerability of new medications may help people with sarcomas, lymphomas and other cancers.

Dr. Jianguo Huang to lead the Preclinical Cancer Therapy Laboratory with a focus on bridging sarcoma research and immunotherapy

Providence researcher awarded National Institutes of Health grant to lead a new lab focusing on the discovery of novel inflammatory pathways in cancer that are targets for therapeutic intervention.

Two investigator-initiated trials sponsored by the Earle A. Chiles Research Institute are currently recruiting patients with either advanced HER2-positive or HR positive/HER2 negative breast cancer.

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinicians at Providence Cancer Institute working to create a living drug for incurable cancers.

May 20 is International Clinical Trials Day. Clinical trials are evidence-based studies in people that result in the biggest breakthroughs in cancer research.

Two new clinical trials available at Providence will evaluate whether a combination of medications are effective and safe therapies for people with metastatic melanoma and metastatic uveal melanoma.

Investigator-initiated clinical trial at Providence Cancer Institute to evaluate the safety and efficacy of using a combination of immunotherapy and radiation therapy on tumors.

A new phase I clinical trial available at Providence Cancer Institute of Oregon will evaluate the efficacy of new immunotherapy designed to modulate the immune system in blood cancer patients.

Clinical studies focus on finding new ways to treat colorectal cancer, prevent recurrence and improve survival outcomes.

People with gallbladder cancer, bile duct cancer or pancreatic cancer may be eligible to participate in new clinical trials available at Providence Cancer Institute of Oregon.

Researchers at Providence Cancer Institute are studying how well two surgical procedures work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

A new study at Providence Cancer Institute tests the effectiveness of an experimental treatment and chemotherapy to inhibit tumor growth in people with lung cancer.

Providence Cancer Institute breast cancer experts are researching new treatments for women with triple-negative breast cancer and HER-2 positive breast cancer.

Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

Providence Cancer Institute to offer a new phase I/II study of a first-in-class photoimmunotherapy for solid tumors that overexpress the epidermal growth factor receptor protein.